Stuart Dorman serves as Chief Commercial Officer at IDEAYA Biosciences, Inc., where they oversee executive responsibilities. Since joining the company, Stuart Dorman has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jan 30, 2026 involved receiving (via award) 155,000 shares valued at $0.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Jan 30, 2026 | IDYA | $0 | Award | 155,000 | $N/A | Discretionary |
Stuart Dorman currently holds 155,000 shares of IDEAYA Biosciences, Inc. (IDYA), valued at approximately $0. This represents their equity stake as Chief Commercial Officer.
Based on SEC Form 4 filings, Stuart Dorman has been a net neutral trader of IDYA stock. They have purchased $0 and sold $0 worth of shares.
Stuart Dorman's most recent insider trade was on Jan 30, 2026, when they sold 155,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted